121 related articles for article (PubMed ID: 32896486)
41. A national evaluation of adjuvant chemotherapy in pT4N0M0 colon cancer from the National Cancer Database.
Reif de Paula T; Keller DS
J Natl Cancer Inst; 2023 Dec; 115(12):1616-1625. PubMed ID: 37584736
[TBL] [Abstract][Full Text] [Related]
42. Is there no need to discuss adjuvant chemotherapy in stage II colon cancer patients with high tumor budding and lymphovascular invasion?
Zenger S; Gurbuz B; Can U; Erginoz E; Ozata IH; Yilmaz SP; Taskin OC; Peker O; Adsay V; Balik E; Bugra D
Langenbecks Arch Surg; 2023 Mar; 408(1):127. PubMed ID: 36973561
[TBL] [Abstract][Full Text] [Related]
43. PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study.
Mihara Y; Hirasaki M; Horita Y; Fujino T; Fukushima H; Kamakura Y; Uranishi K; Hirano Y; Ryozawa S; Yasuda M; Makino Y; Shibazaki S; Hamaguchi T
BMC Gastroenterol; 2023 Oct; 23(1):339. PubMed ID: 37784019
[TBL] [Abstract][Full Text] [Related]
44. Association of time to resection with survival in patients with colon cancer.
Sakowitz S; Bakhtiyar SS; Verma A; Ebrahimian S; Vadlakonda A; Mabeza RM; Lee H; Benharash P
Surg Endosc; 2024 Feb; 38(2):614-623. PubMed ID: 38012438
[TBL] [Abstract][Full Text] [Related]
45. Is the prognosis of T1-2N1 colon cancer the same as that of T1-2N0 colon cancer after curative surgery?
Pian G; Oh SY
Scand J Gastroenterol; 2023; 58(11):1286-1294. PubMed ID: 37345584
[No Abstract] [Full Text] [Related]
46. Prognostic factors and survival disparities in right-sided versus left-sided colon cancer.
Asghari-Jafarabadi M; Wilkins S; Plazzer JP; Yap R; McMurrick PJ
Sci Rep; 2024 May; 14(1):12306. PubMed ID: 38811769
[TBL] [Abstract][Full Text] [Related]
47. Rural versus urban commuting patients with stage III colon cancer: is there a difference in treatment and outcome?
Gaffley M; Hsieh MC; Li T; Yi Y; Gibbs JF; Wu XC; Gallagher J; Chu QD
Surg Endosc; 2023 Dec; 37(12):9441-9452. PubMed ID: 37697118
[TBL] [Abstract][Full Text] [Related]
48. Adherence to stage-specific treatment guidelines for patients with colon cancer.
Chagpar R; Xing Y; Chiang YJ; Feig BW; Chang GJ; You YN; Cormier JN
J Clin Oncol; 2012 Mar; 30(9):972-9. PubMed ID: 22355049
[TBL] [Abstract][Full Text] [Related]
49. Predictors of disease recurrence after radical resection and adjuvant chemotherapy in patients with stage IIb-IIIa squamous cell lung cancer: A retrospective analysis.
Senchukova MA; Kalinin EA; Volchenko NN
World J Exp Med; 2024 Mar; 14(1):89319. PubMed ID: 38590307
[TBL] [Abstract][Full Text] [Related]
50. Colon cancer in France: evidence for improvement in management and survival.
Faivre-Finn C; Bouvier-Benhamiche AM; Phelip JM; Manfredi S; Dancourt V; Faivre J
Gut; 2002 Jul; 51(1):60-4. PubMed ID: 12077093
[TBL] [Abstract][Full Text] [Related]
51. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer.
Chon HY; Lee HS; Sung YN; Tae YK; Park CH; Leem G; Kim SJ; Jo JH; Chung MJ; Park JY; Park SW; Hong SM; Bang S
Sci Rep; 2024 Feb; 14(1):2942. PubMed ID: 38316853
[TBL] [Abstract][Full Text] [Related]
52. Predictive factors associated with relapse of stage II/III colon cancer treated with peroral anti-cancer agents in the adjuvant setting.
Mizuuchi Y; Tanabe Y; Sada M; Kitaura Y; Nagai S; Watanabe Y; Tamiya S; Nagayoshi K; Ohuchida K; Nakano T; Nakamura M
Mol Clin Oncol; 2021 Jun; 14(6):122. PubMed ID: 33936595
[TBL] [Abstract][Full Text] [Related]
53. Chemotherapy reduces long-term quality of life in recurrence-free colon cancer survivors (LaTE study)-a nationwide inverse probability of treatment-weighted registry-based cohort study and survey.
Malik YG; Benth JŠ; Hamre HM; Faerden AE; Ignjatovic D; Schultz JK
Colorectal Dis; 2024 Jan; 26(1):22-33. PubMed ID: 38036898
[TBL] [Abstract][Full Text] [Related]
54. Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse.
Sallinger K; Gruber M; Müller CT; Bonstingl L; Pritz E; Pankratz K; Gerger A; Smolle MA; Aigelsreiter A; Surova O; Svedlund J; Nilsson M; Kroneis T; El-Heliebi A
J Transl Med; 2023 Aug; 21(1):528. PubMed ID: 37543577
[TBL] [Abstract][Full Text] [Related]
55. Value of Real-World Evidence for Treatment Selection: A Case Study in Colon Cancer.
Shen L; van Gestel A; Prinsen P; Vink G; van Erning FN; Geleijnse G; Kaptein M
JCO Clin Cancer Inform; 2024 May; 8():e2300186. PubMed ID: 38753347
[TBL] [Abstract][Full Text] [Related]
56. Role of Peri-operative Chemotherapy in Stage II (pT2N0) Gallbladder Cancers.
Kunte A; Patkar S; Chaudhari V; Goel M
J Gastrointest Surg; 2023 Jan; 27(1):78-88. PubMed ID: 36279092
[TBL] [Abstract][Full Text] [Related]
57. Oncological outcomes of elective versus emergency surgery for colon cancer: A tertiary academic center experience.
Bin Traiki TA; AlShammari SA; AlRabah RN; AlZahrani AM; Alshenaifi ST; Alhassan NS; Abdulla MH; Zubaidi AM; Al-Obeed OA; Alkhayal KA
Saudi J Gastroenterol; 2023; 29(5):316-322. PubMed ID: 37006086
[TBL] [Abstract][Full Text] [Related]
58. Risk factors that impact long-term outcomes in sigmoid colon cancer with urinary bladder involvement.
Balaban V; Sedakov I; Bondarenko N; Zolotukhin S; He M; Tsarkov P
Langenbecks Arch Surg; 2023 Dec; 409(1):22. PubMed ID: 38157060
[TBL] [Abstract][Full Text] [Related]
59. Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy.
Marino G; Grassi T; De Ponti E; Negri S; Testa F; Giuliani D; Delle Marchette M; Dell'Oro C; Fumagalli D; Donatiello G; Besana G; Marchetta L; Bonazzi CM; Lissoni AA; Landoni F; Fruscio R
Front Oncol; 2024; 14():1330481. PubMed ID: 38371620
[TBL] [Abstract][Full Text] [Related]
60. Primary colon lymphomas: An analysis of our experience over the last 18 years.
Hasturk D; Akturk Esen S; Buyukaksoy M; Civelek B; Seven I; Uncu D
Medicine (Baltimore); 2024 May; 103(19):e38013. PubMed ID: 38728507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
